SG Healthcare Signs Additional Medical Device Supply Agreement with Uzbekistan

SG Healthcare , a company specializing in artificial intelligence (AI)-based imaging diagnostic medical devices, announced on the 1st that it has signed a contract to supply an additional 1.7 billion won worth of medical devices to Uzbekistan.

This contract is a follow-up to the 12.6 billion won supply contract signed in June, and is said to be a result of the positive evaluation of the performance of the mobile X-ray fluoroscopy device 'GARION' from local medical institutions and the government.

"Garion" is a C-shaped mobile X-ray device equipped with a 12-inch flat panel display (FPD) capable of outputting high-resolution, real-time images. The device features AI-based denoising technology, jointly developed with the Korea Advanced Institute of Science and Technology (KAIST), which improves image quality while simultaneously reducing radiation exposure. The product also received US FDA 510(k) clearance in 2022.

SG Healthcare explained, "This order was secured based on the Uzbek government's confidence in the performance and quality of previously delivered products." They added, "As our AI-powered imaging diagnostic equipment demonstrates its competitiveness locally, we anticipate expanding our export potential to overseas markets, including the Commonwealth of Independent States (CIS) region."

This contract also sets the stage for SG Healthcare to improve its performance in the second half of the year. The company anticipates a rebound in performance, fueled by continued global demand for high-value-added medical devices, including the Garion, the Invictus magnetic resonance imaging (MRI) device featuring AI acceleration solutions, and the Dominus computed tomography (CT) device.

Kim Jeong-su, CEO of SG Healthcare, said, “As AI technology’s impact on diagnostic accuracy and efficiency grows, ‘Garion’ is a device that condenses our technological prowess,” and added, “Through continuous research and development, we will strengthen our global market competitiveness in the AI-based medical device field.”


  • See more related articles